Ars Pharmaceuticals, Inc. (SPRY)
NASDAQ:SPRY
Want to see SPRY full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.48Last Year’s EPS
-0.46Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress (robust YoY prescription and revenue growth, regulatory approvals, expanded coverage and new affordability programs), backed by a healthy cash balance and a clear plan to scale through the back-to-school season and refill cycles. However, execution risks remain: significant SG&A spend and cash burn, prior-authorization friction that still limits access for a meaningful portion of covered lives, notable prescription abandonment, and uncertainty around timing of key payer decisions (e.g., CVS Caremark). On balance, the positives around growth, access expansion, regulatory wins and commercial initiatives outweigh the operational challenges, but the company remains execution- and timing-dependent over the coming quarters.Company Guidance
Strong top-line growth and prescription momentum
Q1 2026 total revenue of $22.7 million, including $17.5 million in U.S. net product revenue for neffy. Neffy volume in Q1 was ~3x year-over-year (roughly +200% vs. prior-year Q1) and revenue was reported as more than double year-over-year (>100% YoY). The company added ~29,500 new neffy patients in Q1, bringing the U.S. installed base to ~120,000 patients.
Expanded commercial coverage and affordability initiatives
Approximately 90% commercial coverage with 57% of covered lives accessible without prior authorization. Launched a retail $199 cash-price program so patients with rejected commercial claims who fill at retail will pay no more than $199 (previously the $199 cash price was limited to specialty/telehealth channels). Florida Medicaid added unrestricted coverage effective July 1, bringing total unrestricted Medicaid coverage to 9 states.
Regulatory and international wins broaden addressable market
FDA removed the minimum age restriction from the neffy label (enabling pediatric patients >33 lbs and under 4 years access). Health Canada approved neffy as the first needle-free emergency treatment for allergic reactions; commercial launch by partner ALK planned later in 2026. European Commission granted marketing authorization for Euro neffy 1 mg.
Commercial execution and field expansion
Sales force expanded to 148 representatives in May with prioritized targeting of high-volume prescribers. Over 28,000 HCPs have prescribed neffy, with ~50% demonstrating repeat use. Neffy-in-Schools program reported over 200 successful uses, supporting familiarity and caregiver comfort.
Point-of-sale conversion and reduced prescription friction
Implemented a pharmacy-level automatic conversion for denied claims (using established vendor networks covering ~90% of pharmacies) to present a $199 cash option at point of sale, intended to reduce abandonment and negative prescriber feedback. Company reports ~55% of scripts currently go through retail and ~45% via the Blink/specialty channel.
Cash runway and path to profitability
Ended Q1 with $201 million in cash, cash equivalents and short-term investments. Management expects revenue to be back-half weighted and targets cash-flow breakeven by mid-2027, with gross-to-net currently in the low- to mid-50% range and a long-term retention target of ~50%.
SPRY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SPRY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2026 | $7.94 | $7.42 | -6.49% |
Mar 09, 2026 | $9.06 | $9.05 | -0.11% |
Nov 10, 2025 | $8.85 | $8.88 | +0.34% |
Aug 13, 2025 | $16.66 | $15.82 | -5.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ars Pharmaceuticals, Inc. (SPRY) report earnings?
Ars Pharmaceuticals, Inc. (SPRY) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Ars Pharmaceuticals, Inc. (SPRY) earnings time?
Ars Pharmaceuticals, Inc. (SPRY) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SPRY EPS forecast?
SPRY EPS forecast for the fiscal quarter 2026 (Q2) is -0.48.